8
Oct
2024

Valpharma International SpA

Exhibitor at CPHI Milan 2024 stand 10C59, Finished Dosage Formulations
About Us

Since more than 40 years, VALPHARMA has been specialized in the development and contract manufacture of modified release products in capsules (hard-soft) and tablets, with own technology, supplying them to pharmaceutical companies worldwide. Its own R&D Department develops annually many new products in modified release form with own patents, changing posology from three or more daily dosings into once-twice daily dosing, optimizing pharmaceutical effects and reducing side-effects. Authorized by the Italian, Brazilian, Iranian, Ivory Coast, Japanese, Turkish, Taiwanese and United Arab Emira...

  • IT
  • 2015
    On CPHI since
Contact info
Event information
CPHI Milan 2024
  • 08 Oct 2024 - 10 Oct 2024
  • Fiera Milano, Italy
  • Visit us at stand 10C59, Finished Dosage Formulations

Products Featured at CPHI Milan 2024

  • DILTIAZEM HCl S.R. CAPSULES 200 mg - 300 mg - (New Product)

    Product DILTIAZEM HCl S.R. CAPSULES 200 mg - 300 mg - (New Product)

    Valpharma provides a wide range of products which inlcudes DILTIAZEM HCl S.R. CAPSULES 200 mg - 300 mg for the treatment of hypertension, angina pectoris and some types of arrhythmia.Diltiazem is a nondihydropyridines (non-DHP) calcium channel blocker used in the therapy and prophylaxis of coronary ins...
  • GLICLAZIDE S.R.  TABLETS 30 mg   -   (New Product)

    Product GLICLAZIDE S.R. TABLETS 30 mg - (New Product)

    Valpharma provides a wide range of products which includes GLICLAZIDE S.R. TABLETS 30 mg for the therapy of maturity onset Diabetes Mellitus (non-insulin-dependant or Type II), where dietary management alone has been  insufficient.Gliclazide is an oral hypoglycemic used for the control of blood glucos...
  • MELATONIN S.R. TABLETS 2 mg (New product)

    Product MELATONIN S.R. TABLETS 2 mg (New product)

    Valpharma provides a wide range of pharmaceutical products among which  MELATONIN S.R TABLETS 2 mg (a product under development).Melatonin S.R. tablets 2 mg is indicated as monotherapy for the short-term treatment of primary insomnia characterized by difficulty in getting to sleep and in keeping t...
  • E.C. ESOMEPRAZOLE 20 mg and 40 mg capsules (Product under development)

    Product E.C. ESOMEPRAZOLE 20 mg and 40 mg capsules (Product under development)

    Gastro-resistant capsules indicated for the treatment of acid-reflux disorders.
  • I.R. APIXABAN 2,5 mg and 5 mg tablets (Product under development)

    Product I.R. APIXABAN 2,5 mg and 5 mg tablets (Product under development)

    Anticoagulant (blood thinner) that reduces blood clotting and reduces the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.